Novartis enters IMPRESS
Novartis joins the IMPRESS oncology study with six of its cancer medicines to treat up to one hundred patients.
New partners join precision medicine consortium
Five new partners have joined CONNECT.
Meet our new competence broker
Eva S. Dugstad is our new research and industry facilitator aka competence broker for Oslo-based companies.
Turning offices into laboratories
Office spaces have transformed into laboratories in Oslo Cancer Cluster Incubator.
Celebrating the 10th International Cancer Cluster Showcase
ICCS 2021 highlighted success stories and promising newcomers in oncology innovation.
Visions for cancer innovation in Norway
Oslo Cancer Cluster gathered the Norwegian oncology community for a mid-year update in June.
